Swiss registry for TNF-alpha blockers in children and adolescents with rheumatological diseases

• Published in: Praxis (Bern. 1994) Vol. 99; no. 11; pp. 649 - 654
• Main Authors: Sauvain, M J, Schalm, S B, Bérthet, G, Bolz, D, Cannizzaro, E, Hofer, M, Kaiser, D, Saurenmann, R K, Bolt, I B
• Format: Journal Article
• Language: German
• Published: Switzerland 26.05.2010
• Subjects: Adolescent; Adverse Drug Reaction Reporting Systems; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Arthritis, Juvenile - drug therapy; Child; Drug Interactions; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G - adverse effects; Immunoglobulin G - therapeutic use; Infliximab; Product Surveillance, Postmarketing; Receptors, Tumor Necrosis Factor - therapeutic use; Registries; Rheumatic Diseases - drug therapy; Switzerland; Treatment Outcome; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Uveitis - drug therapy; Switzerland
• ISSN: 1661-8157
• DOI: 10.1024/1661-8157/a000144

We created a registry to evaluate long term outcome, efficacy and adverse events for children treated wit TNF-alpha inhibitors in Switzerland. 106 patients (68 female/38 male) were included. 61 patients were treated with Etanercept (Enbrel) and 45 with Infliximab (Remicade). Concomitant treatment at baseline included corticosteroids in 26% and Methotrexate in 75% of the patients. Subjective disease activity three months after initiation of TNF-alpha was better in 81%, worse in 4% and stable in 15% of the patients. In total 24 adverse events in 21 patients were reported. Treatment with TNF-alpha inhibitors seems to be safe and effective for children and adolescents with rheumatologic diseases.